Thrombin-JMI net sales totaled $37 million during the first quarter of 2010 compared to $47 million in the first quarter of last year. Net sales of Avinza totaled $23 million compared to $39 million in the first quarter of 2009.
Marc Goodman – UBS....And then can you talk about THROMBIN a little bit. It just – our understanding is that pricing had stabilized a little bit and share had stabilized but it just seems like this product just keeps going down, I mean you can give us the flavor of how should we think about it. Thanks.
Joe Squicciarino.......THROMBIN, yes so yes we had seen price settle down in the marketplace. The comparison that we’re now making now of course is first quarter of this year versus the first quarter of last year, where price is still a factor. The decline versus last year’s first quarter, once again is split evenly between price and volume, but fortunately we’ve seen price stabilize and hopefully it’ll stay that way.
Source:Seekingalpha
No comments:
Post a Comment